Nothing Special   »   [go: up one dir, main page]

MX2015011957A - Anticuerpos biespecificos anti-tnf-anti-il-17. - Google Patents

Anticuerpos biespecificos anti-tnf-anti-il-17.

Info

Publication number
MX2015011957A
MX2015011957A MX2015011957A MX2015011957A MX2015011957A MX 2015011957 A MX2015011957 A MX 2015011957A MX 2015011957 A MX2015011957 A MX 2015011957A MX 2015011957 A MX2015011957 A MX 2015011957A MX 2015011957 A MX2015011957 A MX 2015011957A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
tnf
tnfa
psa
interleukin
Prior art date
Application number
MX2015011957A
Other languages
English (en)
Inventor
Donmienne Doen Mun Leung
Barrett Allan
Jirong Lu
Andrew Lawrence Glasebrook
Ying Tang
Andrew Charles Vendel
Derrick Ryan Witcher
Pauliina Yachi Pia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2015011957A publication Critical patent/MX2015011957A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos biespecíficos que unen específicamente tanto Factor de necrosis de tumor alfa (TNFa) como interleucina-17 (IL-17). Los anticuerpos biespecíficos de la invención son útiles para tratar varias enfermedades autoinmunes, incluyendo artritis reumatoide (RA), artritis psoriática (PsA) y espondilitis anquilosante (AS).
MX2015011957A 2013-03-08 2014-03-04 Anticuerpos biespecificos anti-tnf-anti-il-17. MX2015011957A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774909P 2013-03-08 2013-03-08
PCT/US2014/020062 WO2014137961A1 (en) 2013-03-08 2014-03-04 Anti-tnf-anti-il-17 bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2015011957A true MX2015011957A (es) 2016-04-07

Family

ID=50343854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011957A MX2015011957A (es) 2013-03-08 2014-03-04 Anticuerpos biespecificos anti-tnf-anti-il-17.

Country Status (16)

Country Link
US (1) US9416182B2 (es)
EP (1) EP2964674B1 (es)
JP (1) JP6152433B2 (es)
KR (1) KR20150113199A (es)
CN (1) CN105283467B (es)
AP (1) AP2015008709A0 (es)
AR (1) AR094872A1 (es)
AU (1) AU2014226093A1 (es)
BR (1) BR112015018203A2 (es)
CA (1) CA2896888C (es)
EA (1) EA201591478A1 (es)
ES (1) ES2654681T3 (es)
MX (1) MX2015011957A (es)
TW (1) TW201444867A (es)
WO (1) WO2014137961A1 (es)
ZA (1) ZA201506568B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10098931B2 (en) 2014-05-15 2018-10-16 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising immunoglobulins
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
TW201639596A (zh) * 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
AR103477A1 (es) 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
WO2017113181A1 (zh) * 2015-12-30 2017-07-06 深圳先进技术研究院 IgG杂合型抗TNFα和IL-17A双特异性抗体
US20170218092A1 (en) * 2016-01-28 2017-08-03 Janssen Biotech, Inc. Bispecific Anti-TNF-Alpha/IL17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their Use
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
EP3483283A4 (en) * 2016-07-08 2019-07-24 Tak-Circulator Co., Ltd. METHOD OF SCREENING MEDICAMENTS FOR PREVENTING OR TREATING DISEASES CAUSED BY INTERLEUKIN 6, INTERLEUKIN 13, TNF, G-CSF, CXCL1, CXCL2 OR CXCL5, AND MEANS FOR PREVENTING OR TREATING DISEASES THREATENED BY INTERLEUKIN 6, INTERLEUKIN 13 , TNF, G-CSF, CXCL1, CXCL2 OR CXCL5
CN107857818A (zh) * 2017-08-07 2018-03-30 上海科新生物技术股份有限公司 一种针对IL‑17和TNF‑α的双特异性融合蛋白
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
CA3086199A1 (en) * 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
CN112930358B (zh) * 2018-11-05 2023-02-21 北京韩美药品有限公司 抗TNFα/抗IL-17A天然抗体结构样异源二聚体形式双特异抗体及其制备
KR20210122243A (ko) 2019-01-31 2021-10-08 누맙 세러퓨틱스 아게 ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
WO2022072291A1 (en) * 2020-09-30 2022-04-07 Amgen Inc. Cation exchange chromatography process
WO2022258045A1 (zh) * 2021-06-11 2022-12-15 山东先声生物制药有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP5063612B2 (ja) 2005-12-13 2012-10-31 イーライ リリー アンド カンパニー 抗ｉｌ−１７抗体
CA3147069A1 (en) * 2007-12-26 2009-07-09 Xencor, Inc. Fc variants with altered binding to fcrn
BRPI1013688A8 (pt) 2009-03-05 2017-02-14 Abbott Lab Proteínas de ligação de il-17.
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Also Published As

Publication number Publication date
EA201591478A1 (ru) 2016-03-31
US20140255406A1 (en) 2014-09-11
AR094872A1 (es) 2015-09-02
CA2896888A1 (en) 2014-09-12
US9416182B2 (en) 2016-08-16
EP2964674A1 (en) 2016-01-13
BR112015018203A2 (pt) 2017-08-22
ZA201506568B (en) 2017-11-29
CN105283467A (zh) 2016-01-27
JP2016510743A (ja) 2016-04-11
KR20150113199A (ko) 2015-10-07
ES2654681T3 (es) 2018-02-14
WO2014137961A1 (en) 2014-09-12
JP6152433B2 (ja) 2017-06-28
AU2014226093A1 (en) 2015-07-23
AP2015008709A0 (en) 2015-09-30
CA2896888C (en) 2017-11-21
TW201444867A (zh) 2014-12-01
CN105283467B (zh) 2019-04-02
EP2964674B1 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
MX2015011957A (es) Anticuerpos biespecificos anti-tnf-anti-il-17.
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
PH12018501778A1 (en) Antibodies to tigit
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
PH12016501908A1 (en) Bispecific antibodies that bind to cd38 and cd3
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
PH12016502491A1 (en) Bispecific heterodimeric diabodies and uses thereof
MX2018013038A (es) Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
EA201491622A1 (ru) Биспецифические антитела против baff и ил-17
PH12015502090A1 (en) Pan-elr+cxc chemokine antibodies
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
MX2018007221A (es) Moleculas de anticuerpos que se unen al factor de necrosis tumoral alfa (tnf alfa).
NZ771169A (en) Antibodies that bind human c6 and uses thereof
GEP20197053B (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof